--- title: "Yili Chuanning Bio: Net profit in the third quarter was 157 million yuan, a year-on-year decrease of 49.44%" type: "News" locale: "en" url: "https://longbridge.com/en/news/262870652.md" description: "Yili Chuanning Bio announced that its revenue for the third quarter was 1.087 billion yuan, a year-on-year decrease of 13.76%; net profit was 157 million yuan, a year-on-year decrease of 49.44%. Revenue for the first three quarters was 3.436 billion yuan, a year-on-year decrease of 22.90%; net profit was 611 million yuan, a year-on-year decrease of 43.17%" datetime: "2025-10-27T10:33:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/262870652.md) - [en](https://longbridge.com/en/news/262870652.md) - [zh-HK](https://longbridge.com/zh-HK/news/262870652.md) --- # Yili Chuanning Bio: Net profit in the third quarter was 157 million yuan, a year-on-year decrease of 49.44% Yili Chuanning Bio announced that its revenue for the third quarter was 1.087 billion yuan, a year-on-year decrease of 13.76%; net profit was 157 million yuan, a year-on-year decrease of 49.44%. Revenue for the first three quarters was 3.436 billion yuan, a year-on-year decrease of 22.90%; net profit was 611 million yuan, a year-on-year decrease of 43.17% ### Related Stocks - [301301.CN](https://longbridge.com/en/quote/301301.CN.md) ## Related News & Research - [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md) - [REG - Nomura Intl. PLC Spire Healthcare Grp - Form 8.3 - SPIRE HEALTHCARE GROUP PLC](https://longbridge.com/en/news/296096467.md) - [Singapore's OUE strengthens China presence with Shenzhen flagship](https://longbridge.com/en/news/296056716.md) - [12:46 ETNovi AMS Launches Amplify: AI That Already Knows Your Association](https://longbridge.com/en/news/296131230.md) - [PharmaTher selects PD Labs as US center of excellence for PERSONALIZ3D platform commercialization](https://longbridge.com/en/news/296225346.md)